Mobile website
Basic Research
Cytotoxic activity of DC-CIK cells derived from non-remission leukemia patients against leukemia cells
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate the cytotoxicity of dendritic cells-cytokine-induced killer cells (DC-CIK cells) derived from patients with remission leukemia or a non-remission disease against leukemia cells. Methods: Blood was sampled from 7 seven patients with refractory non-remission acute leukemia and 7 patients with remission leukemia who were admitted to the Department of Hematology, Hebei Medical University-Affiliated Second Hospital between April 25, 2013 and June 17, 2014. Peripheral blood mononuclear cells (PBMCs) were isolated and induced into DC-CIK cells by conventional methods. The proportions of CD3+CD8+ and CD3+CD56+ cells in the induced DC-CIK cell population were assessed by flow cytometry. Their proliferation rate was calculated and their killing activity against K562 cells and mononuclear cells were determined by CCK-8 assay. Results: DC-CIK cells derived from both patients with a remission disease and patients with a non-remission disease proliferated at similarly rapid rates ( P >0.05). Proportions of CD3+CD8+ and CD3+CD56+ cells increased dramatically with time in both groups of DC-CIK cells ( P <0.05) but there was no significant difference between the two groups ( P >0.05). After 15 days of induction, no leukemia cells were found and the proportion of CD34+ cells was significantly reduced in DC-CIK cell preparations as compared with untreated PBMCs (\[0.1±0.05\]% vs \[8.3±3.1\]%, P <0.05). At effector to target cell ratios from 5 ∶1 to 20 ∶1, DC-CIKs derived from both groups of patients displayed a similar cytotoxic activity against K562 cells ( P >0.05), but DC-CIKs derived from patients with a non-remission disease had a significantly higher cytotoxic activity against mononuclear cells ( P <0.05). Conclusion: DC-CIK cells derived from PBMCs of both patients with non-remission leukemia and patients with remission leukemia have similar proliferative activities, similar profiles of CD3+CD8+ and CD3+CD56+ expression and similar cytotoxic activities against K562 cells. However, DC-CIK cells from patients with non-remission leukemia display a higher sensitivity against autologous mononuclear cells.
Keywords:
Project Supported:
Project supported by the Research Foundation for the Doctoral Program of Higher Education of China (No. 200800890011)
Clc Number:
